12.88  1.19 (10.18%)		04-14 16:00
Open: 12.1 High: 13.22 Volume: 40,624		Pre. Close: 11.69 Low: 11.69 Market Cap: 472(M)

Short term
Mid term
Targets	6-month :	15.44	1-year :	18.03
Resists	First :	13.22	Second :	15.44
Pivot price	10.39
Supports	First :	9.64	Second :	7.42
MAs	MA(5) :	11.86	MA(20) :	9.94
	MA(100) :	8.05	MA(250) :	4.88
MACD	MACD :	0.6	Signal :	0.4
%K %D	K(14,3) :	83.3	D(3) :	81.3
RSI	RSI(14): 66.4
52-week	High :	16.34	Low :	1.11

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ARMP ] has closed below upper band by 7.2%. Bollinger Bands are 89.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	13.23 - 13.28	13.28 - 13.34
Low:	11.56 - 11.61	11.61 - 11.67
Close:	12.78 - 12.87	12.87 - 12.97

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Thu, 09 Apr 2026
ARMP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Fri, 03 Apr 2026
Armata Pharmaceuticals Sets Timeline for 2026 Annual Meeting - The Globe and Mail

Thu, 02 Apr 2026
Armata Pharmaceuticals sets June 11, 2026 for annual stockholders meeting - TradingView — Track All Markets

Wed, 25 Mar 2026
Auditor flags going concern as Armata ends 2025 with $14.1M cash - Stock Titan

Thu, 19 Mar 2026
Armata pushes back earnings as FDA backs Phase 3 staph blood infection study - Stock Titan

Thu, 12 Mar 2026
Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.